

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **JOINN LABORATORIES (CHINA) CO., LTD.**

### **北京昭衍新藥研究中心股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6127)**

### **SUPPLEMENTAL ANNOUNCEMENT**

Reference is made to the announcement issued by JOINN Laboratories (China) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on 27 April 2023 in relation to the connected transaction contemplated in the Power Capacity Increase Agreement (the “**Announcement**”). Unless otherwise specified in this announcement, terms used herein shall have the same meanings as those defined in the Announcement.

The Company wishes to provide further information on the identities of the ultimate beneficial owners of Qixi Bio. As at the date of the Announcement, to the best of the Directors’ knowledge, information and belief having made all reasonable enquiries, Qixi Bio is owned as to 65% by Beijing Qixi Yizhao Investment Co., Ltd.\* (北京七溪亦昭投資有限公司) (“**Beijing Qixi**”) and 35% by Taicang Xiangtang Haohua Real Estate Co., Ltd.\* (太倉香塘滬華置業有限公司) (“**Taicang Xiangtang**”).

Beijing Qixi is a limited liability company established in the PRC which is wholly-owned by Yizhao (Beijing) Pharmaceutical Technology Co., Ltd.\* (熠昭(北京)醫藥科技有限公司), which is in turn owned as to 47.6% by Mr. Zhou, 37.4% by Ms. Feng, 5% by Mr. Zuo, 5% by Mr. Zhang Hongshan (張洪山) and 5% by Ms. Li Tao (李濤). Ms. Feng and Mr. Zhou collectively held 55.25% effective equity interest in Qixi Bio accordingly.

Taicang Xiangtang is a limited liability company established in the PRC which is wholly-owned by Suzhou Xiangtang Haohua Technology Development Co., Ltd.\* (蘇州香塘滬華科技發展有限公司) which is in turn owned as to 52% by Xiangtang Group Co., Ltd. (香塘集團有限公司) and 48% by Taicang City Construction Investment Group Co., Ltd.\* (太倉市城市建設投資集團有限公司). Xiangtang Group Co., Ltd. is owned as to 55% by Mr. Gu Jianping (顧建平) and 45% by Mr. Gu Zhenqi (顧振其). Taicang City Construction Investment Group Co., Ltd. is ultimately wholly-owned by State-owned Assets Supervision and Administration Office of Taicang Municipal Government (太倉市政府國有資產監督管理辦公室).

\* For identification purpose only

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, except for Mr. Zhou, Ms. Feng and Mr. Zuo, Qixi Bio's ultimate beneficial owners are Independent Third Parties.

Save as disclosed in this announcement, all information in the Announcement remains unchanged.

By order of the Board  
**JOINN Laboratories (China) Co., Ltd.**  
**Feng Yuxia**  
*Chairperson*

Beijing, the PRC  
3 May 2023

*As at the date of this announcement, the Board comprises Ms. Feng Yuxia as the Chairperson and executive Director, Mr. Zuo Conglin, Mr. Gao Dapeng, Ms. Sun Yunxia and Dr. Yao Dalin as executive Directors, and Mr. Sun Mingcheng, Dr. Zhai Yonggong, Mr. Ou Xiaojie and Mr. Zhang Fan as independent non-executive Directors.*